Engineering the Next Wave of Antibody-Based Cancer Therapeutics

• 1756 · PDF Novel HER2 antibody drug conjugates with stable hydrophilic linkers Zhiying Zou, Sichang Zhou, Jin Chu, Xueping Jiang, Zhongliang Jiang, Jing Ming Dong, Feng Bai, Jing Pan, Yuzhong Chen, Can Mao, Qun Sun, Lucas Pan, Greg Witham, Xiaoyu Wang, Gann Xu, Bingsen Zhou, Kai Qi, Lin Wang, Ray Yin
• 1757 · PDF Synergy of BCL-2 and MEK/HDAC inhibition in IBC and non-IBC models: Potential for a first IBC specific therapy Hassan Zbib, Habib Serhan, Maryam Nakhjiri, Rhea Raghavan, Tusharika Rastogi, Peter J. Ulintz, Aki Morikawa, Nathan Merrill, Sofia Merajver
• 1758 · PDF Targeted DNA damage through SSTR2: Preclinical development of a novel peptide-drug conjugate for neuroendocrine tumors Gianluca Fossati, Daniela Modena, Luca Menin, Michela Bottani, Andrea Stevenazzi, Barbara Vergani, Elisabetta Galbiati, Andrea Resovi, Matteo Tironi, Serena Cecchetti, Francesca Spadaro, Maria Carollo, Rosita Lupi, Barbara Valsasina, Paolo Orsini, Silvia Castelli, Italo Beria, Christian Steinkühler
• 1759 · PDF Targeting LRRC15 with an aptamer-drug conjugate achieves complete tumor growth inhibition Kristin Thompson, Aaron Ball, Jin Yuan, Yuxun Wang, Doo Young Jung, Shuhao Zhu
• 1760 · PDF Preclinical characterization of XB404, a masked anti-ROR1/2 antibody-drug conjugate Kathleen R. Gogas, Christine M. Janson, Hui Zhao, Fang Wang, Bee-Cheng Sim, Brian A. Mendelsohn, Penelope M. Drake, Robyn M. Barfield, Thomas Linz, Maxine Bauzon, Dharmaraj Samuel, Minjong Park, Inna Vainshtein, Jackie Cheng, Seema Kantak
• 1761 Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models Yutaro Mori, Ryo Tamura, Kotaro Takahashi, Kosuke Yoshihara
• 1762 · PDF An avidity-driven, dual-targeting ADC with superior tumor selectivity for the treatment of solid tumors Steffen Runz, Paul Sauter, Sebastian Latwiel, Jennifer Volkind, Jawad Iqbal, Wilma Neumann, Helga Groetsch, Dina Osmanovic, Abdul-Habib Maag, Anja Schreiber, Christine Köhler, Tatjana Schneidt, Anna Pryszlak, Christoph Erkel, Richard J. Austin
• 1763 BSI-737, a best-in-class B7H3xPD-L1 bi-specific ADC with dual function to eliminate tumor via selective killing and exacerbated anti-tumor immune response Hui-Han Hu, Xiaoyao Hao, Yue Gao, Hongyan Li, Jinyu Liu, Jinge Zhao, Yi Lu, Liezhou Ji, Zhigang Ma, Mingjiu Chen, Kedan Lin
• 1764 MC003: A novel bi-epitope, dual-payload, fixed-combination chemoimmunotherapy antibody drug conjugate for the treatment of folate receptor alpha-expressing ovarian cancer Seah H. Lim, Hailiang Zheng, Peipei Zhong
• 1765 · PDF YL413: A novel dual-payload anti-HER2 antibody-drug conjugate demonstrating potent preclinical activity Hanwen Deng, Tao Wang, Wei Lian, Tingting Mao, Qing Zong, Chun Deng, Bingsong Xie, Tongtong Xue, Jiaqiang Cai
• 1766 · PDF Dual EGFR and Bcl-2 inhibition overcomes resistance in sinonasal squamous cell carcinoma Rhea Raghavan, Athena Apfel, Habib Serhan, Angel Qin, Chia-Jen Liu, Maryam Nakhjiri, Sofia D. Merajver, Aaron Udager, Nathan Merrill
• 1767 · PDF Preclinical efficacy of a first-in-class anti-SLC3A2 ADC in hard-to-treat solid and hematologic malignancies Qinhong Ma, Daizong Li, Kewei Zhao, Mary Q. Xu, Mason Lu
• 1768 High-sensitivity targeted mass spectrometry enables quantification of HLA-presented antigens for TCR-T therapeutic target discovery Simonas Savickas, Anamarija Pfeiffer, Arthur Viodé, Liliana Malinovska, Oliver Bernhardt, Veronique Laforte, Lucy Yang, Roland Bruderer, Daniel Redfern, Yuehan Feng, Wayne Paes
• 1769 LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits enhanced antitumor activity in combination with standard-of-care therapies in preclinical ovarian cancer models Zhaohai Lu, Chun Ping Yu, Jack A. Dempsey, Wei Guo Xu, Lisa Kays, Bonita D. Jones, Andrew Capen, Xueqian Gong
• 1770 · PDF Differential in vitro activity of amivantamab, cetuximab, and panitumumab against EGFR ECD resistance mutations Stacey L. Lehman, Himanshu Gupta, Rosa MF Cardoso, Laura A. Struzyna, Stephen W. Jarantow, Xuesong Lyu, Elsie Samakai, Emrullah Yilmaz, Sanjib Chowdhury, Joshua C. Curtin, Bharvin Patel
• 1771 Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate (IMMU-132) and Apo2L/TRAIL in triple negative breast cancer (TNBC) Yonit Addissie, Yoshimi Endo Greer, Stan Lipkowitz
• 1772 HER3-targeted nano-bioparticles deliver 5′-triphosphate-modified FOXC1 siRNA to induce tumor regression and immune activation in HER3⁺ cancers Amirhesam Babajani, Felix Alonso-Valenteen, James Teh, Nelyda Gonzalez, Simoun Mikhael, Michelle Wong, Xiaojiang Cui, Ravinder Abrol, Lali K. Medina-Kauwe
• 1773 Development and characterisation of a novel monoclonal antibody against overexpressed integrin alpha6beta4 on human pancreatic cells Gustavo Arias, Angus G. Dalgleish, Izhar Bagwan, Said Khelwatty, Satvinder Mudan, Tony Walker, Helmout Modjtahedi
• 1774 · PDF ACR317, a novel CDH17-ADC, shows potent efficacy in preclinical gastrointestinal cancer models Zhenwei Miao, Feng Wang, Yaowu Li, Shanhui Weng, Li Yang
• 1775 ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and broad antitumor activity in preclinical models of solid tumors Zhenwei Miao, Feng Wang, Shanwei Weng, Li Yang, Wu Yao
• 1776 ALK101sc, a novel afucosylated bispecific antibody targeting EGFR and c-MET with common light chain demonstrates potent, broad-spectrum antitumor activity Li Li, Hongwang He, Mengfan Peng, Meiyu Yang, Jiajia Pan, Hui Feng
• 1777 FL116, a PD-1/IL-18 bispecific antibody, enables cis-activation of PD-1⁺ T cells and reshapes the suppressive tumor microenvironment (TME) Haiming Huang, Quanxiao Li, Xiaotuan Zhang, Liwen Ji, Yanling Wu, Dong Wei, Tianlei Ying

在完整检索应用中浏览本分会场 →